Chongkundang unit Kyungbo Pharma wins court stay on drug approval cancellations pending appeal

• Chongkundang Holdings issued a correction on its unit Kyungbo Pharmaceutical’s product-approval cancellation tied to a business suspension filing.
• A court granted an injunction suspending the cancellation’s effect until 30 days after the appellate ruling in the main case.
• The filing keeps the affected sales exposure at KRW 13.48 billion, equal to 5.65% of 2024 revenue.
• Suspension start date remains June 24, 2025.
• Further disclosure planned depending on the appeals court’s decision on the merits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chongkundang Holdings Corp. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930800443), on September 30, 2026, and is solely responsible for the information contained therein.